deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT04599634

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

A Phase 1 Study of Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Sponsor: National Cancer Institute (NCI)

Conditions B-Cell Lymphoma Chronic Lymphocytic Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma
Interventions 18-FDG-PET Acetaminophen Bone Marrow Aspiration Bone Marrow Biopsy CT Scan chest/abdomen/pelvis Diphenhydramine MRI Magrolimab Methylprednisolone Obinutuzumab Prednisone/prednisolone Venetoclax
Updated 40 times since 2020 Last updated: Jan 13, 2025 Started: Dec 16, 2021 Primary completion: Mar 29, 2024 Completion: Jun 20, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on B-Cell Lymphoma and Chronic Lymphocytic Lymphoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 40 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – present · 17 months · monthly snapshot

Change History

40 versions recorded

  1. Mar 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Mar 2025 [monthly]

    Completed PHASE1

  3. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE1

  5. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 35 earlier versions

  1. Apr 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE1

  4. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE1

  5. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE1

  6. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  7. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1

  8. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1

  9. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1

  10. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE1

  11. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1

  12. Apr 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

  13. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE1

  14. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE1

  15. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE1

  16. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  17. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

  18. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  19. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

    Status: Suspended → Recruiting

  20. May 2022 — Jun 2022 [monthly]

    Suspended PHASE1

  21. Apr 2022 — May 2022 [monthly]

    Suspended PHASE1

  22. Mar 2022 — Apr 2022 [monthly]

    Suspended PHASE1

    Status: Recruiting → Suspended

  23. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  24. Dec 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE1

  25. Nov 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE1

  26. Oct 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE1

  27. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE1

  28. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE1

  29. May 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE1

  30. Apr 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE1

  31. Mar 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE1

  32. Feb 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE1

  33. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE1

  34. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1

  35. Nov 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations